Abstract
Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003
Journal of clinical oncology, Vol.36(15_suppl), pp.4558-4558
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.4558
Abstract
Abstract only
Details
- Title: Subtitle
- Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003
- Creators
- Arkadiusz Z. Dudek - University of Illinois at ChicagoLi C Liu - University of Illinois at ChicagoAjjai Shivaram Alva - University of Michigan–Ann ArborMark Stein - Rutgers, The State University of New JerseyShilpa Gupta - University of MinnesotaCostantine Albany - Indiana University – Purdue University IndianapolisMonika Joshi - Penn State Milton S. Hershey Medical CenterYousef Zakharia - Georgia Regents Medical CenterJoshua Michael Lang - University of Wisconsin Carbone Cancer CenterJames K. Schwarz - University of Nebraska Medical CenterAnas Al-Janadi - Michigan State University
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.4558-4558
- DOI
- 10.1200/JCO.2018.36.15_suppl.4558
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548376902771
Metrics
5 Record Views